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A B S T R A C T   
Objectives: Preeclampsia is associated with hypertension in later life, but the underlying pathophysiological 
mechanisms remain uncertain. We aimed to explore whether the angiogenic markers soluble Fms-like tyrosine 
kinase-1 (sFlt-1) and placental growth factor (PlGF) measured in women with preeclampsia could be associated 
with hypertension 1 year after delivery. 
Methods: This is a secondary analysis of a prospective cohort study, originally aimed to evaluate the use of sFlt-1/ 
PlGF ratio to predict adverse outcome in women with (suspected) preeclampsia. Office blood pressure (BP) was 
evaluated at 1 year postpartum in women who had a confirmed diagnosis of preeclampsia within one week of 
biomarker measurement. 
Results: Eighty women were included with a median (interquartile range) gestational age (GA) at biomarker 
measurement of 30 (27–33) weeks. Twenty-three (29%) women had hypertension 1 year postpartum. These 
women showed higher median SBP during their pregnancy and lower GA at PE diagnosis compared to women 
without hypertension. Median PlGF levels were lower in women with hypertension 1 year postpartum compared 
to women without hypertension (23 vs. 48 pg/mL, p = 0.017), while no differences in sFlt-1 or sFlt-1/PlGF ratio 
were observed. Multivariable analysis adjusted for GA did not show significant association between PlGF (nor 
sFlt-1, sFlt-1/PlGF ratio) and hypertension 1 year postpartum (OR [95% CI] 0.9 [0.2–4.4], p = 0.97). 
Conclusion: Our data indicate that sFlt-1, PlGF or their ratio measured during pregnancy are not suitable for the 
prediction of hypertension 1 year postpartum and hence guiding follow-up of women with previous 
preeclampsia.   
1. Introduction 
Preeclampsia is a severe hypertensive disorder affecting 5–7% of all 
pregnancies. It is characterized by the new onset of hypertension 
accompanied by either proteinuria, utero-placental dysfunction such as 
intrauterine growth restriction and/or other maternal organ dysfunction 
at or after 20 weeks gestation [1]. Preeclampsia not only has significant 
impact on maternal and fetal health during pregnancy [2], but has also 
been established as a risk factor of cardiovascular disease for both 
mother and offspring [1]. A recent study reported that about 42% of 
women with severe preeclampsia already show some form of hyper-
tension 1 year after pregnancy [3]. Unfortunately, our knowledge of 
factors that could predict the development of hypertension (or other 
cardiovascular disease) or not, is limited. Identification of these factors 
could enable clinicians to determine which women with previous pre-
eclampsia require earlier follow-up after delivery. 
Although the underlying pathophysiology of preeclampsia is not 
completely elucidated, an imbalance between circulating pro- and 
antiangiogenic factors, reflected by elevated soluble Fms-like tyrosine 
kinase-1 (sFlt-1) and low placental growth factor (PlGF) levels has been 
well established [1]. This high antiangiogenic state inducing a pro- 
inflammatory state and endothelial dysfunction is thought to play a 
key role in the disorder. In fact, endothelial dysfunction has been re-
ported to persist up to 15 years after preeclampsia [4]. 
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We have reported that plasma PlGF levels were independently 
associated with mean arterial pressure during pregnancy [5] whereas 
the severity of hypertension itself is a predictor for the development of 
future hypertension [6]. Although sFlt-1, PlGF and their ratio have been 
investigated widely for the prediction of preeclampsia [7] and 
preeclampsia-related pregnancy outcomes [8], their role in prediction of 
postpartum hypertension or cardiovascular disease in later life has not 
yet been determined. 
Therefore, we aimed to evaluate whether the angiogenic imbalance 
during preeclampsia could predict hypertension 1 year after pregnancies 
complicated by preeclampsia. 
2. Methods 
2.1. Study design and participants 
This was a secondary analysis of a prospective observational cohort 
study conducted from 2012 to 2016 at the Erasmus Medical Center, 
Rotterdam, the Netherlands, originally aimed to evaluate the usefulness 
of the sFlt-1/PlGF ratio to predict adverse pregnancy outcome in 408 
women with suspected or confirmed preeclampsia. Written informed 
consent to participate in the study, which was approved by the local 
research ethics committee (MEC-2013-202), was obtained from all 
participants. For the current analysis, women with pre-existing hyper-
tension and/or proteinuria were excluded (n = 117). In order to assess 
the biomarker values at the time of confirmed preeclampsia, we 
excluded women who did not have confirmed preeclampsia within one 
week of study entry (time of biomarker measurement) (n = 136). 
Women who had a follow-up appointment at the Internal Medicine 
clinician and/or at the Follow-Up Pre-Eclampsia (FUPEC) Outpatient 
Clinic at the Erasmus Medical Center, Rotterdam, within 9 to 15 months 
postpartum were included in the analysis. 
2.2. Preeclampsia diagnosis 
Preeclampsia was defined according to the definition of the Inter-
national Society for the Study of Hypertension in Pregnancy (ISSHP) of 
2018; de novo hypertension (diastolic blood pressure [DBP] of ≥90 
mmHg or systolic blood pressure [SBP] of ≥140 mmHg) accompanied 
by ≥1 of the following new-onset conditions at or after 20 weeks’ 
gestation: proteinuria (urinary protein-to-creatinine ratio [uPCR] ≥ 30 
mg/mmol or ≥300 mg/24 h or 2+ dipstick), acute kidney injury (AKI) 
(creatinine ≥90 µmol/L; 1 mg/dL), neurological complications (e.g. 
eclampsia), hematological complications (thrombocytopenia-platelet 
count <150.000/µL, disseminated intravascular coagulation, hemoly-
sis), liver involvement (elevated transaminases, e.g.: alanine amino-
transferase [ALAT] or aspartate aminotransferase >40 IU/L) with or 
without right upper quadrant or epigastric abdominal pain, or utero-
placental dysfunction (fetal growth restriction, abnormal umbilical ar-
tery (UA) Doppler wave form analysis or stillbirth) [9]. HELLP 
syndrome, defined as hemolysis, elevated liver enzymes and low platelet 
count, was now also considered as preeclampsia according to the ISSHP 
2018 criteria [9]. 
2.3. Data collection 
Serum for the analysis of sFlt-1 and PlGF was collected at inclusion of 
the original study. Serum was stored at − 80 ◦C after centrifugation, until 
analysis. All samples were measured postpartum. Measurement of sFlt-1 
and PlGF was performed using an automated analyzer (Cobas 6000, e- 
module; Roche Diagnostics, Mannheim, Germany). Clinical data during 
and after pregnancy including demographic information, gestational 
age (GA) at biomarker measurement, diagnosis and delivery, physical 
examination, laboratory test results and pregnancy outcome were 
attained from the electronic medical records of the patients and ascer-
tained by two independent researchers (R.I.N and A.M.J.F). Time to 
delivery was defined as the amount of days between study entry (at time 
of biomarker measurement) and delivery. 
2.4. Outcome measures at 1-year follow-up 
A trained nurse or research assistant measured office BP with the 
participant in the upright sitting position after 5 min of rest. The 
appropriate arm cuff was placed around the right upper arm to measure 
BP with a validated oscillometric device. Women were not allowed to 
speak during BP measurements. 
Hypertension based on office BP was defined according to the Eu-
ropean Society of Hypertension and European Society of Cardiology: 
office hypertension (average SBP of ≥140 mmHg and/or an average DBP 
of ≥90 mmHg) and/or the use of antihypertensive medication. 
2.5. Statistical analysis 
Data are reported as median (interquartile range) for continuous 
variables and as number (percentage) for categorical variables. Normal 
distribution for continuous variables was assessed using the Shapiro- 
Wilk W test. To investigate the difference between non-parametric 
continuous data, Mann Whitney U test was performed. The Fisher’s 
exact (in the case of a small sample size, ≤5) and Chi-square were used 
to assess differences between two categorical variables. Spearman rank- 
order correlation was applied to calculate correlation coefficients. A 
non-response analysis was performed to evaluate baseline characteris-
tics between women that were included and women lost to follow-up. 
Logistic regression analysis was performed to study the association be-
tween potential predictors (i.e., biomarkers) and postpartum hyperten-
sion at 1 year follow-up. Biomarkers evaluated in univariable analysis 
included sFlt-1, PlGF and sFlt-1/PlGF ratio. Due to the fact that GA at 
time of biomarker measurement can affect the levels of these bio-
markers, multivariable analysis was performed to correct for GA at 
biomarker measurement. Because of the limited number of events (n =
23), we were unable to adjust for additional confounders. Clinical pa-
rameters such as nulliparity, highest SBP during pregnancy, pre-
conceptional BMI, time to delivery, GA at delivery and at preeclampsia 
diagnosis were evaluated as predictors in univariable analysis. The 
discriminative ability of the models was assessed using concordance- 
statistic (C-statistic) which is equivalent to the area under the ROC 
curve for dichotomous outcomes. To evaluate the added value of sFlt-1, 
PlGF or their ratio when corrected for GA at measurement, we fitted a 
logistic regression model containing sFlt-1, PlGF or sFlt-1/PlGF ratio and 
a logistic regression model containing both GA at measurement and one 
of the angiogenic markers. sFlt-1, PlGF or sFlt-1/PlGF ratio were 
considered to have additional value if the likelihood ratio test 
comparing both models was statistically significant. SPSS Statistics 21 
(IBM Corporations) and R Software were used for the statistical analysis. 
3. Results 
3.1. Patient demographics 
The final population for analysis consisted of 80 women (Fig. 1). 
Patient characteristics during pregnancy and at 1 year follow-up of all 
participants (aged 20–43) are shown in Table 1. Median (interquartile 
range) GA at study entry (biomarker measurement) was 30 weeks 
(27–33). Fifty-nine women (74%) were nulliparous, and eight women 
(10%) had a previous history of preeclampsia. Preconceptional BMI (kg/ 
m2) was 23 (22–27). The median highest SBP during pregnancy was 157 
(140–165) mmHg, the median highest uPCR was 98 (38–262) g/mol and 
the median sFlt-1/PlGF ratio was 296 (68–602). GA at delivery was 30 
(28–34) weeks. At 1 year follow-up, the overall SBP normalized to 124 
(114–135) mmHg, whereas 3 women (4%) still had proteinuria (uPCR 
≥ 30 g/mol). 
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3.2. Patient characteristics and angiogenic markers according to 
hypertension at 1 year follow-up 
Of the 80 women, 23 (29%) had hypertension 1 year after pregnancy 
(Table 1). Compared to women without hypertension, participants with 
hypertension had a lower GA at PE diagnosis (27 vs. 30 weeks, p < 0.01) 
and were more often nulliparous (91% vs 67%, p = 0.03). The highest 
median SBP during pregnancy was higher in women with hypertension 
1 year postpartum (168 vs. 155 mmHg, p = 0.02), while their GA at 
delivery (28 vs. 31, p < 0.01) and birth weight (955 vs. 1350, p < 0.01) 
were lower in comparison to women without hypertension (Table 1). 
Women with hypertension at 1 year more often had HELLP syndrome 
during their pregnancy (57% vs. 28%, p = 0.02), but this difference was 
most likely due to higher SBP in this group. Nine women were still using 
antihypertensive medication after 1 year, suggesting they had persistent 
hypertension. Median gestational PlGF levels were lower in women with 
hypertension 1 year postpartum in comparison to women without hy-
pertension (23 [14–50] vs. 48 [23–80] pg/mL, p = 0.02), while no 
differences in sFlt-1 or sFlt-1/PlGF ratio were observed between the two 
groups (Table 1, Fig. 2). Median GA at study entry (biomarker mea-
surement) was three weeks earlier in the hypertension group (Table 1). 
The non-response analysis showed that women without follow-up had 
milder forms of preeclampsia, as observed by the later GA at study entry 
(35 vs. 30 weeks, p < 0.01), GA at delivery (37 vs. 30 weeks, p < 0.01) 
and lower sFlt-1/PlGF ratio (67 vs. 296, p < 0.01). No differences in age, 
race or parity were observed (Table 2). 
3.3. Prediction of hypertension based on office BP at 1 year follow-up 
The clinical parameters nulliparity and highest SBP were signifi-
cantly associated with the occurrence of hypertension at 1 year follow- 
up, although their discriminative ability was limited (C-index of 0.62, p 
= 0.04 and C-index of 0.65, p = 0.04) (Table 3A). The GA at delivery 
showed good value to predict postpartum hypertension with a C-index of 
0.72, while GA at diagnosis performed significantly better as a contin-
uous value in comparison to the cut-off value of 34 weeks (C-index =
0.73, p < 0.001 vs. C-index of 0.61, p = 0.06). PlGF was not significantly 
associated with the occurrence of hypertension at 1 year (C-index =
0.67, OR [95% CI] 0.3 [0.1–0.9], p = 0.06), neither were sFlt-1 or the 
sFlt-1/PlGF ratio. When corrected for GA at biomarker measurement in 
multivariable analysis, the model with angiogenic markers showed no 
significant association with the occurrence of hypertension at 1 year 
postpartum (Table 3B). 
3.4. Correlations between angiogenic markers and BP during and after 
pregnancy 
Angiogenic markers were evaluated in women during pregnancy 
Fig. 1. Flowchart of in- and exclusion criteria in this study. PE indicates preeclampsia. HT indicates hypertension; sFlt-1, soluble Fms-like tyrosine kinase-1; PlGF, 
placental growth factor. 
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(with and without follow-up, n = 155) and at follow-up, as depicted in 
Table 4. sFlt-1 and sFlt-1/PlGF ratio showed a significant negative cor-
relation with GA at inclusion (r = − 0.193 and r = − 0.539, p < 0.001), 
while PlGF showed a positive correlation with GA at inclusion (r =
0.672, p < 0.001). The angiogenic markers did not significantly corre-
late with SBP or DBP at inclusion, but both PlGF and sFlt-1/PlGF ratio 
showed a significant correlation with highest SBP and DBP during 
pregnancy. No significant correlations between sFlt-1, PlGF or sFlt-1/ 
PlGF ratio and office BP at 1 year follow-up were observed. 
4. Discussion 
In this study of 80 women with previous preeclampsia, we examined 
whether the angiogenic factors sFlt-1, PlGF and sFlt-1/PlGF ratio could 
be associated with postpartum hypertension at 1 year follow-up based 
on office BP measurements. Twenty-nine percent of women in our 
cohort showed office hypertension 1 year after pregnancy. This per-
centage was lower than recently reported in 200 women with severe 
preeclampsia (42%) [3], however in that study hypertension was diag-
nosed by 24-h ambulatory BP measurements (ABPM). Hence, the 
discrepancy between these numbers is most likely explained by women 
with masked hypertension who are missed by an office BP measurement 
alone. Indeed, about 18% of women in that study had masked hyper-
tension [3]. 
When evaluating the angiogenic factors, we found lower levels of the 
proangiogenic factor PlGF in women with office hypertension at 1 year 
follow-up. However, this marker did not show significant value to pre-
dict hypertension 1 year after delivery, even when corrected for GA at 
time of biomarker measurement in multivariable analysis. Moreover, 
both sFlt-1 and sFlt-1/PlGF ratio showed limited predictive performance 
to determine whether women had hypertension both in uni- and 
multivariable analysis, suggesting that their levels during preeclampsia 
are not associated with persistence or the development of hypertension 
1 year after delivery. These observations remained similar when eval-
uating hypertension based on 24-h ABPM at 1 year postpartum in a small 
subset of women (n = 49) (data not shown). 
That women with previous preeclampsia are at increased risk of CVD 
including chronic hypertension in later life has been well established 
[10]. Whether this is an effect of pre-pregnancy cardiovascular risk 
factors or a direct consequence of preeclampsia itself, remains a matter 
of debate. Despite our understanding that a high antiangiogenic state 
(reflected by elevated sFlt-1 and low PlGF levels) is a key mechanism 
underlying endothelial dysfunction in preeclampsia [5], only a few 
studies evaluated the relationship between these factors and the 
Table 1 
Patient demographics of all included women and according to hypertension 
based on office BP.  







80 57 23  
Age at study entry, 
yrs 
30 (27–34) 30 (27–35) 29 (27–34) 0.59 
GA at study entry*, 
wks 
30 (27–33) 30 (29–33) 27 (26–30) <0.01 
Preconceptional 
BMI, kg/m2 
23 (22–27) 23 (21–26) 26 (23–30) 0.07  
Race, n (%)     
White 56 (70) 37 (65) 19 (83) 0.18 
Black 9 (11) 6 (11) 3 (13) 0.71 
Other 15 (19) 14 (25) 1 (4) 0.06 
Nulliparous, n (%) 59 (74) 38 (67) 21 (91) 0.03 
Smoking at 
inclusion, n (%) 
4 (5) 3 (5) 1 (4) 1.00 
History of PE, n 
(%) 
8 (10) 8 (14) 0 (0) 0.10  
Clinical 
parameters     
GA at diagnosis 
PE, wks 












97 (90–105) 95 (90–105) 100 (91–110) 0.18 
Antihypertensive 
drug use at study 
entry, n (%) 
56 (70) 40 (70) 16 (70) 0.96 
Highest uPCR, g/ 
mol 
98 (38–262) 104 (40–240) 59 (24–397) 0.37 












67 (58–73) 65 (58–73) 68 (60–73) 0.74 
Highest ALAT, U/L 47 (24–175) 33 (20–169) 81 (38–193) 0.06 













125 (66–172) 0.04 
HELLP syndrome, 
n (%) 












96 (88–105) 90 (86–103) 100 (95–107) 0.09  
Pregnancy 
Outcome     
GA at delivery, 
wks 
30 (28–34) 31 (29–34) 28 (27–31) <0.01 











percentile < 10, 
n (%) 
20 (25) 15 (26) 5 (22) 1.00 
Time to deliveryǂ, 
days 
2 (1–8) 2 (1–8) 4 (2–12) 0.06  
Angiogenic 
Markers     







PlGF, pg/mL 32 (18–69) 48 (23–80) 23 (14–50) 0.02 
sFlt-1/PlGF ratio 296 (68–602) 208 (62–580) 498 (92–704) 0.24 
sFlt-1/PlGF ratio 
≤ 38, n (%) 
11 (14) 8 (14) 3 (13) 1.00 
sFlt-1/PlGF ratio 
≥85, n (%) 
56 (70) 38 (67) 18 (78) 0.42   
Table 1 (continued ) 






up     







Office DBP, mmHg 76 (70–83) 73 (68–80) 86 (79–95) <0.01 
BMI, kg/m2 25 (23–30) 24 (22–29) 29 (24–31) 0.17 
Antihypertensive 
drug use, n (%) 
9 (11) 0 (0) 9 (39) <0.01 
uPCR ≥ 30 g/mol 3 (4) 3 (5) 0 (0) 0.25 
Hypertension defined as office SBP ≥ 140 mmHg and/or office DBP ≥ 90 mmHg 
and/or antihypertensive drug use. Values are median (interquartile range) or 
number (percentage). GA, gestational age; BMI, body mass index; PE, pre-
eclampsia; SBP, systolic blood pressure; DBP, diastolic blood pressure; uPCR, 
urinary protein-to-creatinine ratio; LD, lactate dehydrogenase; ALAT, alanine- 
aminotransferase; sFlt-1 indicates soluble Fms-like tyrosine kinase-1; PlGF, 
placental growth factor. P-value depicts difference between hypertension and no 
hypertension group. *Biomarkers were determined at time of study entry. ǂTime 
to delivery is defined as the amount of days between study entry and delivery. 
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occurrence of hypertension postpartum. In a cohort of 988 women, Goel 
et al. [11] demonstrated that antepartum levels of the angiogenic 
markers were independently associated with persistent or de novo hy-
pertension postpartum. While these findings are in contrast with our 
observations, they only evaluated the development of hypertension up 
to six weeks postpartum. Interestingly, a recent large study (n = 5475) 
showed that lower mid-pregnancy (mean 20.6 weeks of gestation) serum 
PlGF levels were associated with higher systolic blood pressure six and 
nine years after pregnancy [12]. Of note, the latter study mostly eval-
uated PlGF levels in uncomplicated pregnancies, which differs from our 
population consisting only of women with preeclampsia. In addition, the 
effect of lower mid-pregnancy PlGF levels on systolic blood pressure was 
very limited (i.e. regression coefficient β [95% CI] of 1.8 [0.35–3.2] 
mmHg in comparison to women with high PlGF) [12]. It is also impor-
tant to note that the GA at time of biomarker measurement in our cohort 
was much later (median 27 weeks). Possibly, the contribution of PlGF to 
blood pressure is evident only when considering all pregnancies 
(including cases of mild preeclampsia or gestational hypertension) and 
can no longer be detected when focusing on women with only severe 
features of preeclampsia. Indeed, when we compared pregnancy char-
acteristics between the women included in this study and the women 
that were lost to follow-up, it seems that our cohort consisted mostly of 
women with severe forms of preeclampsia, as reflected by the higher 
sFlt-1 and lower PlGF levels, and earlier GA at study entry and delivery 
(Table 2). We also evaluated other factors during pregnancy that could 
be associated with postpartum hypertension and found that the GA 
when preeclampsia occurred showed the highest value to predict the 
occurrence of hypertension 1 year postpartum. Interestingly, the 
continuous value of GA showed significantly better prediction than a 
cut-off value of 34 weeks (early-onset vs. late-onset). Indeed, some 
studies have shown that both women with early and late-onset pre-
eclampsia are at risk of developing hypertension postpartum [13,14] 
Fig. 2. sFlt-1, PlGF and sFlt-1/PlGF ratio levels in the 80 women according to 
the occurrence of hypertension at 1 year follow-up. sFlt-1 indicates soluble Fms- 
like tyrosine kinase-1, PlGF, placental growth factor. 
Table 2 
Difference in Pregnancy Characteristics between Included Women (n = 80) and 
Women that were Lost to Follow-Up (n = 75).  




80 75  
Age at study entry, yrs 30 (27–34) 32 (27–35) 0.39 
GA at study entry, wks 30 (27–33) 35 (31–37) <0.01 
Preconceptional BMI, kg/m2 23 (22–27) 25 (22–30) 0.11  
Race, n (%)    
White 56 (70) 46 (61) 0.30 
Black 9 (11) 16 (21) 0.08 
Other 15 (19) 13 (17) 0.68 
Nulliparous, n (%) 59 (74) 46 (61) 0.10 
Smoking at inclusion, n (%) 4 (5) 4 (5) 1.00 
History of PE, n (%) 8 (10) 9 (12) 0.69  
Clinical parameters    
GA at diagnosis PE, wks 30 (27–33) 36 (31–40) <0.01 
Highest SBP, mmHg 157 (140–165) 150 (140–160) 0.41 
Highest DBP, mmHg 97 (90–105) 99 (90–100) 0.94 
Antihypertensive drug use, n 
(%) 
56 (70) 44 (59) 0.18 
Highest uPCR, g/mol 98 (38–262) 57 (32–153) 0.18 
Highest Uric acid, mmol/L 0.37 (0.32–0.44) 0.36 (0.31–0.41) 0.44 
Highest Creatinine, µmol/L 67 (58–73) 69 (56–78) 0.56 
Highest ALAT, U/L 47 (24–175) 18 (13–35) <0.01 
Highest LD, U/L 289 (223–443) 235 (198–292) <0.01 
Lowest Platelet Count, 109/L 149 (100–203) 163 (137–216) 0.04  
Pregnancy Outcome    
GA at delivery, wks 30 (28–34) 37 (32–38) <0.01 
Girls, n (%) 40 (50) 30 (40) 0.43 
Birth weight, grams 1210 (863–1798) 2505 
(1435–3190) 
<0.01 
Birth weight percentile <10, 
n (%) 
20 (25) 14 (19) 0.44 
Time to deliveryǂ, days 2 (1–8) 5 (2–12) 0.08  
Angiogenic Markers    





PlGF, pg/mL 32 (18–69) 74 (44–127) <0.01 
sFlt-1/PlGF ratio 296 (68–602) 67 (25–197) <0.01 
Values are median (interquartile range) or number (percentage). PE indicates 
preeclampsia; GA, gestational age: SBP, systolic blood pressure; DBP, diastolic 
blood pressure; uPCR, urinary protein-to-creatinine ratio; LD, lactate dehydro-
genase; ALAT, alanine-aminotransferase; sFlt-1, soluble Fms-like tyrosine 
kinase-1; PlGF, placental growth factor. *Biomarkers were determined at time of 
study entry. ǂTime to delivery is defined as the amount of days between study 
entry and delivery. 
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while others have reported increased risk of chronic hypertension when 
preeclampsia occurred <37 weeks in comparison to >37 weeks [10]. 
However, none of these studies reported the continuous value of GA, 
which should be considered in future studies. Our observation that GA at 
delivery, highest SBP during pregnancy and nulliparity were signifi-
cantly associated with postpartum hypertension, supports the concept 
that the severity of the features of preeclampsia is an important deter-
mining factor [3,6,15]. Factors at 1 year postpartum that could influence 
blood pressure such as oral contraceptive use or breastfeeding were not 
taken into account due to the retrospective nature of this study. How-
ever, an effect of breastfeeding is not expected since ~85% of women 
already stop breastfeeding after 6 months [16]. 
Our study has some limitations. First of all, the number of women 
evaluated in this study is limited. A significant proportion of the initial 
study population (~50%) were lost to follow-up, which were mostly 
women with milder forms of preeclampsia. Nevertheless, our findings 
indicate that in women with (mostly severe forms of) preeclampsia, 
angiogenic factors are not a determining factor for the occurrence of 
hypertension at 1 year postpartum. Future studies should be conducted 
in a larger and a more heterogeneous group of women to establish 
whether this finding is specific to severe pre-eclampsia or that mild pre- 
eclamptic pregnancies show similar findings. Secondly, since the 
angiogenic markers vary with GA, it is important to evaluate them at a 
fixed time-point, preferably at the end of gestation when the largest 
alteration in biomarker levels occurs. Lastly, future studies should focus 
on defining hypertension based on 24-h ABPM, since this is the most 
reliable method to diagnose hypertension and to identify participants 
with masked and white-coat hypertension. 
In conclusion, this study is the first to assess the relationship between 
angiogenic markers and the occurrence of hypertension 1 year after 
delivery in a cohort of preeclamptic women. Our data illustrates that 
sFlt-1, PlGF and sFlt-1/PlGF ratio are not associated with hypertension 
1 year postpartum, indicating they are not suitable for the prediction of 
hypertension and guiding of follow-up of women with previous (mostly 
severe) preeclampsia. We encourage future prospective studies to 1) 
validate our findings in a larger cohort of preeclamptic women 2) 
evaluate other cardiovascular biomarkers during pregnancy that could 
be associated with postpartum hypertension and other cardiovascular 
disease and lastly 3) to develop prognostic models to adequately stratify 
women who are at increased risk for developing chronic hypertension 
after preeclampsia. 
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